Many pediatric prescriptions go unfilled

Food Insecurity and the Dangers of Infant Formula Dilution

Music therapist Jenna Marcovitz discusses the role of pediatricians in making timely referrals to music therapy to support whole-child health.

January 30th 2023

Phase 3 data show effectiveness of somapacitan in children with growth disorders

Demystifying Infant Formula

Somapacitan was non-inferior and had a similar safety profile and clinical outcomes compared to once-daily somatropin in improving yearly growth rates.

October 11th 2022

INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients

Morgan Ebert, Managing Editor

FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years

Safety, phosphate level gains, and immunogenicity data offer encouraging signals in the pivotal trial.

FDA accepts NDA for berotralstat in HEA patients aged 2 to 11 years | Image credit: Contemporary Pediatrics

Connecting families to music therapy, with Jenna Marcovitz, MA

The federal agency provided BioCryst Pharmaceuticals a target action date of September 12, 2025 for potential approval of berotralstat (ORLADEYO).

Related Content

Jenna Marcovitz, MA, MT-BC, CCLS, RMT

Food Insecurity and the Dangers of Infant Formula Dilution

Music therapist Jenna Marcovitz discusses the role of pediatricians in making timely referrals to music therapy to support whole-child health.

January 30th 2023

Phase 3 data show effectiveness of somapacitan in children with growth disorders

Demystifying Infant Formula

Somapacitan was non-inferior and had a similar safety profile and clinical outcomes compared to once-daily somatropin in improving yearly growth rates.

October 11th 2022

INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients

Morgan Ebert, Managing Editor

FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years

Safety, phosphate level gains, and immunogenicity data offer encouraging signals in the pivotal trial.